−0.02USD
−569.00 KUSD
101.21 MUSD
66.42 M
About CytomX Therapeutics, Inc.
Sector
CEO
Sean A. McCarthy
Headquarters
South San Francisco
Website
Employees (FY)
122
Founded
2010
ISIN
US23284F1057
FIGI
BBG001J472L3
CytomX Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company, which engages in the development of conditionally activated, biologics localized to the tumor microenvironment. The company was founded by Frederick W. Gluck and Nancy E. Stagliano in September 2010 and is headquartered in South San Francisco, CA.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of CTMX is 1.76 USD — it hasn't changed in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange CytomX Therapeutics, Inc. stocks are traded under the ticker CTMX.
CytomX Therapeutics, Inc. is going to release the next earnings report on May 9, 2024. Keep track of upcoming events with our Earnings Calendar.
CTMX stock is 1.71% volatile and has beta coefficient of 2.27. Check out the list of the most volatile stocks — is CytomX Therapeutics, Inc. there?
One year price forecast for CytomX Therapeutics, Inc. has a max estimate of 3.50 USD and a min estimate of 2.00 USD.
CTMX earnings for the last quarter are 0.04 USD whereas the estimation was −0.19 USD which accounts for 121.21% surprise. Estimated earnings for the next quarter are −0.05 USD. See more details about CytomX Therapeutics, Inc. earnings.
CytomX Therapeutics, Inc. revenue for the last quarter amounts to 26.38 M USD despite the estimated figure of 13.34 M USD. In the next quarter revenue is expected to reach 19.60 M USD.
Yes, you can track CytomX Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
CTMX stock has fallen by 16.19% compared to the previous week, the month change is a 12.44% fall, over the last year CytomX Therapeutics, Inc. has showed a 6.67% increase.
CTMX net income for the last quarter is 837.00 K USD, while the quarter before that showed 2.99 M USD of net income which accounts for −72.03% change. Track more CytomX Therapeutics, Inc. financial stats to get the full picture.
Today CytomX Therapeutics, Inc. has the market capitalization of 119.19 M, it has decreased by 3.74% over the last week.
No, CTMX doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, CTMX shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade CytomX Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 18, 2024, the company has 122.00 employees. See our rating of the largest employees — is CytomX Therapeutics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So CytomX Therapeutics, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating CytomX Therapeutics, Inc. stock shows the sell signal. See more of CytomX Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on CytomX Therapeutics, Inc. future price: according to them, CTMX price has a max estimate of 3.50 USD and a min estimate of 2.00 USD. Read a more detailed CytomX Therapeutics, Inc. forecast: see what analysts think of CytomX Therapeutics, Inc. and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. CytomX Therapeutics, Inc. EBITDA is 6.43 M USD, and current EBITDA margin is −4.26%. See more stats in CytomX Therapeutics, Inc. financial statements.